证券代码：002873 证券简称：新天药业 公告编号：2023-031 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司 关于参加"2022年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动"的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 28 日、 2023 年 4 月 28 日在巨潮资讯网分别披露了《2022 年年度报告》、《2023 年一 季度报告》。为进一步加强上市公司与投资者的有效沟通，便于投资者进一步了 解公司 2022 年度经营情况及其他关切问题，公司将参加由贵州证监局指导、贵 州证券业协会与深圳市全景网络有限公司联合举办的"2022 年度贵州辖区上市 公司业绩说明会暨投资者集体接待日活动"，具体安排如下： 一、业绩说明会的安排 召开时间：2023 年 5 月 17 日（星期三）15:30-17:00 召开方式：网络远程方式 公司出席本次活动的人员有：副董事长、副总经理王金华先生；董事、副总 经理兼董事会秘书王光平先生；财务总监曾志辉女士。 参 ...

贵阳新天药业股份有限公司 2023 年第一季度报告 | | | 贵阳新天药业股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减（%） | | --- | --- | --- | --- | | 营业收入（元） | 208,755,879.11 | 249,216,213.05 | -16.24% | | 归属于上市公司股东的净利 | 25,092,336.81 | 30,879,340.57 | -18.74% | | 润（元） | | | | | 归属 ...

债券代码：128091 债券简称：新天转债 证券代码：002873 证券简称：新天药业 贵阳新天药业股份有限公司投资者关系活动记录表 编号：2023-005 | | □特定对象调研 □分析师会议 □媒体采访 □√业绩说明会 | | --- | --- | | 投资者关系活 | | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称 | 通过线上参与公司 年度业绩网上说明会的投资者 2022 | | 及人员姓名 | | | 时间 | 年 月 日 2023 4 12 15:00-17:00 | | 地点 | 深圳证券交易所"互动易"平台、"新天药业投资者关系"微信小程序 | | | 董事长、总经理：董大伦先生 | | 上市公司接待 | 董事、副总经理、董事会秘书：王光平先生 | | 人员姓名 | 财务总监：曾志辉女士 | | | 独立董事：官峰先生 | | | 问题 1、您好，领导，促进公司发展的有利因素很多，那我想咨询一下，公 | | | 司认为哪些方面制约公司业务，谢谢。 | | | 答：第一，企业经营发展优势暨保持稳健可持续增长，已经具备以下几个 | ...

关于举行2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）2022 年年度报告及其摘 要已经第七届董事会第七次会议审议通过。具体内容详见公司指定信息披露媒体 《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）于 2023 年 3 月 28 日发 布的《2022 年年度报告摘要》（公告编号：2023-013），《2022 年年度报告》 （公告编号：2023-012）同日发布于巨潮资讯网（http://www.cninfo.com.cn）。 为便于广大投资者进一步了解公司生产经营情况，公司定于 2023 年 4 月 12 日（星期三）下午 15:00-17:00 在深圳证券交易所"互动易"平台及"新天药业 投资者关系"微信小程序同步举行 2022 年度业绩网上说明会。本次年度业绩说 明会采用网络远程的方式举行，投资者可通过以下两种方式参与互动交流，具体 如下： | 证券代码：002873 | 证券简称：新天药业 | 公告编号：2023-022 | | --- | ...

Financial Performance - The company reported a cash dividend of 1.00 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company’s total revenue for the year 2022 was not explicitly stated in the provided content, but the financial report ensures the accuracy and completeness of the financial statements[3]. - The company's operating revenue for 2022 was ¥1,087,673,294.88, representing a 12.15% increase compared to ¥969,844,472.18 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥116,101,897.84, a 15.40% increase from ¥100,605,308.02 in 2021[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥105,769,379.89, up 12.71% from ¥93,839,366.09 in 2021[20]. - The basic earnings per share for 2022 was ¥0.5007, reflecting a 13.13% increase from ¥0.4426 in 2021[20]. - The total assets at the end of 2022 amounted to ¥1,843,850,779.14, a 20.95% increase from ¥1,524,426,501.68 at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were ¥1,129,201,797.73, which is a 26.81% increase from ¥890,443,409.78 at the end of 2021[20]. - The cash flow from operating activities for 2022 was ¥75,818,174.01, a decrease of 39.00% compared to ¥124,300,304.12 in 2021[20]. - The company received government subsidies amounting to ¥8,234,619.83 in 2022, compared to ¥8,789,898.32 in 2021[27]. Market Position and Strategy - The company plans to expand its market presence and is actively pursuing new product development and technological advancements[4]. - The company is positioned in the traditional Chinese medicine sector, which is experiencing favorable policy support and innovation growth[31]. - The company achieved a market-leading position in the gynecology sector, with its main products reaching over 100 million in market scale[38]. - In the first half of 2022, the company ranked first in sales of gynecological traditional Chinese medicine in public medical institutions, surpassing a 5% market share[39]. - The company plans to optimize its product structure and market distribution, expecting significant growth in business development in the coming years[42]. - The company aims to strengthen its role in public health emergencies and improve the management system for traditional Chinese medicine[36]. - The company is actively expanding its market presence in the field of women's health and reproductive health[44]. - The company has initiated the "Dragon Gate Plan" for market expansion, which is expected to roll out nationwide in 2023[65]. Research and Development - The company is committed to innovation in drug development, emphasizing clinical value and supporting original innovation in pharmaceuticals[34]. - The company has completed clinical phase III trials for three new traditional Chinese medicine products, with 445 varieties of traditional Chinese medicine formula granules and 179 completed national standard filings[47]. - The company holds 30 invention patents, 2 utility model patents, and 13 design patents, with 11 national new drug certificates obtained[48]. - The company has established three R&D platforms, employing 173 technical staff, which accounts for 18.62% of total employees, focusing on traditional Chinese medicine innovation[59]. - The company is enhancing its R&D capabilities and management to improve efficiency and ensure timely product launches[111]. - The company is focusing on brand building, particularly for its OTC brand "He Yan" and aims to establish a strong academic brand among healthcare professionals[112]. Governance and Compliance - The company maintains a strong governance structure, with no regulatory inquiries or compliance issues reported during the year[121]. - The board of directors was restructured, with the addition of two new independent directors to enhance oversight and governance[123]. - The company adheres to strict information disclosure obligations, ensuring that all shareholders receive accurate and timely information[127]. - The company has established a robust independent financial accounting system, allowing for independent financial decision-making and management[136]. - The company has a dedicated internal audit department to oversee significant transactions and ensure compliance with internal control systems[129]. - The company has established a comprehensive governance structure, including a board of directors and various committees to enhance decision-making efficiency[135]. Employee and Talent Management - The company has established a training center to enhance employee skills through a mixed training model, combining online and offline methods[177]. - The company has a dual career development path for employees, focusing on both management and technical skills to support talent retention[177]. - The company has a significant focus on employee performance evaluation and incentive mechanisms to foster a high-efficiency work environment[176]. - The total remuneration for the board of directors, supervisors, and senior management during the reporting period amounted to 759.31 million CNY[163]. - The company has implemented an annual salary system for senior and middle management, along with annual performance evaluations[175]. Financial Management and Investments - The company has committed to invest a total of 45,351.6 million in various projects, with 43,983.07 million already utilized[98]. - The company has not engaged in any significant equity investments during the reporting period[90]. - The company reported a total revenue of 21,351.4 million yuan for the year, an increase from 19,268.1 million yuan in the previous year, representing a growth of approximately 10.8%[103]. - The company plans to enhance its production capacity for traditional Chinese medicine (TCM) formulations, with a revised investment scale of 55.01 million yuan, down from the original 99.58 million yuan[103]. - The company has raised ¥31,702.02 million from its initial public offering, with a net amount of ¥28,969.23 million after deducting issuance costs[96]. Risk Management - The management discussed potential risks and corresponding mitigation strategies in the future outlook section of the report[4]. - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements in the report[4]. - The company is actively monitoring industry policy changes to mitigate risks related to drug pricing and market access[113]. - The company is implementing measures to manage environmental risks associated with production processes, aiming to reduce the proportion of environmental costs in overall expenses[114]. Production and Operations - The company has established a comprehensive production line for various forms of traditional Chinese medicine, including hard capsules, granules, and gels, certified by GMP[41]. - The production process strictly adheres to GMP requirements, with quality supervision at every stage to ensure product compliance[51]. - The company has completed the automation and intelligent upgrades of multiple formulation production lines, with two advanced modern intelligent production lines expected to be completed by June 2023, ensuring a projected capacity demand of 4 billion in value over the next five years[52]. - The company has established long-term stable relationships with suppliers, ensuring quality through comprehensive evaluations and audits[50]. Shareholder Engagement - The company conducted multiple investor relations activities in January 2022, including three research meetings on January 5, 12, and 20, focusing on company introduction and operational conditions[116]. - The company reported a 41.37% investor participation rate in the 2021 Annual General Meeting held on May 9, 2022[137]. - The company has committed to avoiding any competition with its controlling shareholder and has established independent operational and financial practices[132].